Ascendis Pharma, Inc.

147 articles with Ascendis Pharma, Inc.

• Ascendis Pharma A/S To Present At The Stifel 2015 Healthcare Conference

  11/12/2015

• Ascendis Pharma A/S Reports Third Quarter 2015 Financial Results

  11/12/2015

• Ascendis Pharma A/S To Present At Three Upcoming Investor Conferences

  9/4/2015

• Ascendis Pharma A/S Reports Second Quarter 2015 Financial Results

  8/25/2015

• Ascendis Pharma A/S To Report Top-Line Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone And Host Conference Call On Thursday, July 30, 2015 At 9:00 A.M. Eastern Time

  7/30/2015

• Ascendis Pharma A/S Announces Positive Top-line Results From A Phase 2 Pediatric Study Of Once-Weekly TransCon Growth Hormone For The Treatment Of Growth Hormone Deficiency

  7/30/2015

• Ascendis Pharma A/S Reports First Quarter 2015 Financial Results

  5/19/2015

• Ascendis Pharma A/S To Report First Quarter 2015 Financial Results And Host Conference Call On May 18, 2015

  5/11/2015

• Ascendis Pharma A/S To Present At Upcoming Investor Conferences

  5/8/2015

• Ascendis Pharma A/S Announces Results Of Phase 1 Study Of Transcon Treprostinil

  4/29/2015

• Ascendis Pharma A/S Reports Full Year 2014 Financial Results

  3/26/2015

• Ascendis Pharma A/S To Report Full Year 2014 Financial Results And Host Conference Call On March 25, 2015

  3/18/2015

• Ascendis Pharma A/S To Present At ENDO 2015

  3/5/2015

• Ascendis Pharma A/S Announces Closing Of Initial Public Offering, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares

  2/3/2015

• Ascendis Pharma A/S Announces Pricing Of Initial Public Offering

  1/28/2015

• Ascendis Pharma A/S Announces Initiation Of A Phase 1 Single Ascending Dose Study Of Transcon Treprostinil

  1/14/2015

• Growth Hormone Biotech Ascendis Pharma A/S Files For A $86 Million IPO

  12/19/2014

• Ascendis Pharma A/S Announces Positive Six-Month Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency

  12/15/2014

• Ascendis Pharma A/S Completes $60 Million Oversubscribed Series D Financing

  12/1/2014

• Ascendis Pharma A/S Announces Positive Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency

  9/16/2014